Nanobiotix annual revenue
2018
2019
2020
2021
2022
2023
2024
2025
Nanobiotix Revenue Growth & History (NANO)
Nanobiotix reported €29.6M in revenue for fiscal 2025, an increase of 355.34% from the previous fiscal year.
View full Nanobiotix company overviewNanobiotix annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €29.6M | €41.3M | +355.34% |
| 2024 | 2024-12-31 | −€11.6M | −€41.7M | −138.62% |
| 2023 | 2023-12-31 | €30.1M | €25.3M | +529.36% |
| 2022 | 2022-12-31 | €4.8M | €2.1M | +80.43% |
| 2021 | 2021-12-31 | €2.6M | €135,000 | +5.37% |
| 2020 | 2020-12-31 | €2.5M | −€29,000 | −1.14% |
| 2019 | 2019-12-31 | €2.5M | −€938,000 | −26.96% |
| 2018 | 2018-12-31 | €3.5M | — | — |
Nanobiotix revenue growth trends
Over the last five reported fiscal years, revenue grew from €2.5M to €29.6M, a compound annual growth rate of 63.83%.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Nanobiotix source filings ↗Community posts
Nanobiotix reports final melanoma cohort results for radioenhancer combination
Nanobiotix ($NANO) reported updated Phase 1 results in 24 heavily pretreated patients with advanced cutaneous melanoma resistant to anti-PD-1 therapy. Its JNJ-1900, also called NBTXR3, was injected into a tumor before radiotherapy and subse ...
